Novartis Partners in Gene-Editing Pact

By Akia Thorpe -

November 15, 2017

Novartis and Homology Medicines, a Bedford, Massachusetts-based genetic medicines company focused on gene-editing and gene-therapy technology, have agreed to use Homology’s proprietary gene-editing technology to develop new treatments for select ophthalmic targets and a hemoglobinopathy disease.

Under the agreement, Novartis made an upfront payment to and an equity investment in Homology. In addition, Novartis is providing funding to advance the programs and to explore new opportunities for Homology’s technology platform. Homology is also eligible to receive milestone payments from Novartis, plus royalties from the sale of products commercialized under the collaboration.

Source: Homology Medicines